Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment
1 Nov 2016
Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment
Biomarkers of sensitivity and resistance
Editor's ESMO 2016 roundup
CDK4/6 inhibitors for metastatic breast cancer
ESMO 2016 conference highlights
Lurbinectedin in PARP resistant breast cancer
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Highlights of ESMO 2016
Custirsen shows no survival benefit in metastatic prostate cancer
Negative trial results of custirsen for metastatic prostate cancer
Advances for NSCLC in review
Ceritinib following crizotinib relapse for ALK positive NSCLC